Coherus Biosciences | CHRS - Dochód Netto





Dochód Netto Zmiana Data
AbbVie USD 3.61B 2.92B 2026-06
Acadia Pharmaceuticals USD 31.5M 27.86M 2026-06
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 501K 66.98M 2026-06
Alnylam Pharmaceuticals USD 164.49M 41.5M 2026-06
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 2.38B 556M 2026-06
Baxter International USD 126M 141M 2026-06
Biogen USD 97.5M 222M 2026-06
BioMarin Pharmaceutical USD 44.76M 60.76M 2026-06
Bristol-Myers Squibb USD 3.32B 640M 2026-06
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.1B 301M 2026-06
Fujifilm JPY 84.24B 11.58B 2026-03
Gilead Sciences USD -10.5B 12.52B 2026-06
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Merck USD -1.34B 2.9B 2026-06
Myriad Genetics USD -7.9M 19.5M 2025-12
Pacira USD 4.65M 1.74M 2026-06
Perrigo USD 74.5M 473.1M 2026-06
Pfizer USD -248M 2.94B 2026-06
PTC Therapeutics USD -2.81M 132.16M 2026-03
Regeneron Pharmaceuticals USD 1.3B 569.7M 2026-06
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Teva Pharmaceutical Industries USD -576M 945M 2026-06
Vertex Pharmaceuticals USD 1.1B 68.4M 2026-06
Xencor USD -21.73M 107.19M 2026-06
Zoetis USD 691M 90M 2026-06